Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have received a consensus recommendation of “Hold” from the twelve analysts that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $49.50.

GMAB has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, July 18th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Truist Financial increased their price target on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Finally, BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th.

Institutional Trading of Genmab A/S

Institutional investors have recently modified their holdings of the company. Capital International Investors lifted its position in Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares during the last quarter. Harding Loevner LP increased its position in shares of Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after purchasing an additional 85,665 shares in the last quarter. First Trust Advisors LP increased its position in shares of Genmab A/S by 16.0% during the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $5,912,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Genmab A/S by 5.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 165,187 shares of the company’s stock worth $5,260,000 after purchasing an additional 8,463 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Trading Up 0.4 %

GMAB opened at $28.48 on Tuesday. Genmab A/S has a 12 month low of $24.53 and a 12 month high of $41.58. The stock has a 50-day moving average of $27.01 and a 200 day moving average of $28.35. The firm has a market cap of $18.84 billion, a P/E ratio of 23.73, a P/E/G ratio of 1.01 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The firm had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. On average, research analysts forecast that Genmab A/S will post 1.13 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.